The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.

Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.

Shares of BioNTech slipped 0.83% in after-hours trading on Friday after the company said it would pay $791.5 million in a ...

The theory is solid, but creating such a bespoke vaccine quickly enough to be of use is a different matter. “Not many years ago,” says Alan Melcher, a clinical scientist at the Institute of Cancer ...

Geode Capital Management LLC trimmed its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 0.8% during the 3rd quarter, ...

BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University ...

Morgan Stanley analyst Terence Flynn notes that BioNTech (BNTX) announced last week that it had reached a settlement agreement with the ...

Settling royalty disputes and acquiring Biotheus, BioNTech reshapes its future in vaccines and oncology innovation.

In a regulatory filing, BioNTech (BNTX) said, “BioNTech previously disclosed that it was in discussions with the University ...

Pharma majors like BioNTech in Germany and Pfizer in the United States have made profits in billions of dollars in selling ...

BioNTech SE ADR closed $17.54 below its 52-week high ($131.49), which the company achieved on September 17th.

The ADR's fall snapped a three-day winning streak.